Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow EXELIXIS, INC.

Get SEC filing alerts via email and in your feed for EXELIXIS, INC.

EXEL

EXELIXIS, INC.

About EXELIXIS, INC.

Exelixis, Inc. is an oncology-focused biopharmaceutical company developing targeted cancer therapies, primarily through its flagship molecule cabozantinib. Its core business includes marketing approved treatments for kidney, thyroid, liver, and other cancers, alongside a robust pipeline of investigational small molecules and biotherapeutics. The company leverages strategic collaborations and licensing to expand its portfolio, aiming to improve cancer patient outcomes worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from EXELIXIS, INC.

1
1
EXELIXIS, INC. Exelixis Reports 10% Revenue Growth to $610.8 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
EXELIXIS, INC. Exelixis Reports $2.12 Billion in Net Product Revenues for 2025, Driven by Cabozantinib Sales

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
EXELIXIS, INC. Exelixis Reports 11% Revenue Growth to $597.8 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
EXELIXIS, INC. Exelixis Reports Q2 2025 Financial Results with $184.8M Net Income and 11% Revenue Decline

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
EXELIXIS, INC. Exelixis Reports 31% Revenue Growth to $555.4 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
EXELIXIS, INC. Exelixis Reports $1.8 Billion in Net Product Revenues for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
EXELIXIS, INC. Exelixis Reports 12% Revenue Growth, Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments